Russian vaccines against especially dangerous bacterial pathogens

Emerging Microbes and Infections

Volumn 3, Issue 12, 2014, Pages

  Feodorova, Valentina A ^a   Sayapina, Lidiya V ^b   Corbel, Michael J ^c   Motin, Vladimir L ^d  

^a Federal Agency of Scientific Organizations   (Russian Federation)

^b Scientific Centre for Expert Evaluation of Medicinal Products   (Russian Federation)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

anthrax; brucellosis; cholera; glanders; pathogens; plague; tularemia; vaccine

Indexed keywords

ANTHRAX VACCINE; BACTERIAL VACCINE; BRUCELLA VACCINE; CHOLERA VACCINE; GLANDERS VACCINE; PLAGUE VACCINE; TULAREMIA VACCINE; UNCLASSIFIED DRUG;

ANTHRAX; BRUCELLOSIS; CHOLERA; DRUG APPROVAL; GLANDERS; HUMAN; LICENSING; MELIOIDOSIS; NONHUMAN; PLAGUE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RUSSIAN FEDERATION; TULAREMIA; VACCINATION;

BACTERIA (MICROORGANISMS);

EID: 84927935173     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.82     Document Type: Review

References (79)

1. Moskvitina EA, Mazrukho AB, Adamenko OL et al. [Characteristics of the epidemiological situation on cholera the world over.] Problems Part Danger Dis 2013; 1: 11-17. Russian.
2. Onishchenko GG. [Infectious diseases in natural reservoirs: epidemic situation and morbidity in the Russian Federation and prophylactic measures.] Zh Mikrobiol Epidemiol Immunobiol 2001; 3: 22-28. Russian.
3. Revich B, Tokarevich N, Parkinson AJ. Climate change and zoonotic infections in the Russian Arctic. Int J Circumpolar Health 2012; 71: 18792.
4. Aikimbajev A, Meka-Mechenko T, Temiralieva G et al. Plague in Kazakhstan at the present time. Przegl Epidemiol 2003; 57: 593-598.
5. Fetherston JD, Perry RD. The pigmentation locus of Yersinia pestis KIM6+ is flanked by an insertion sequence and includes the structural genes for pesticin sensitivity and HMWP2. Mol Microbiol 1994; 13: 697-708.
6. Kutyrev VV, Eroshenko GA, Kukleva LM et al. [Comparative genetic characteristic of vaccine strain of Yersinia pestis EV and its putative 'virulent derivatives'.] Zh Mikrobiol Epidemiol Immunobiol 2009; 3: 50-56. Russian.
7. Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970; 42: 653-666.
8. Saltykova RA, Faibich MM. [Experience from a 30-year study of the stability of the properties of the plague vaccine strain EV in the USSR.] Zh Mikrobiol Epidemiol Immunobiol 1975; 6: 3-8. Russian.
9. Feodorova VA, Motin VL. Plague vaccines: current developments and future perspectives. Emerg Microbes Infect 2012; 1: e36.
10. Feodorova VA, Motin VL. Plague vaccines. In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens. Kerala: Research Signpost, 2011: 176-233.
11. Girard G. [Vaccination de l'homme contre la peste au moyen de germes vivants (virus vaccin EV). Premiers resultates acquis a Madagascar.] Bull Acad Med 1935; 114: 16-23. French.
12. Aleksandrov NI, Gefen NE, Gapochko KG et al. [Aerosol immunization with dry pulverized anatoxins and vaccines. VIII. Studies on a method of aerosol immunization with pulverized anti-plague vaccine of large numbers of men.] Zh Mikrobiol Epidemiol Immunobiol 1962; 33: 46-50. Russian.
13. Stepanov AV, Marinin LI, Vorob'ev AA. [Aerosol vaccination against dangerous infectious diseases.] Vestn Ross Akad Med Nauk 1999; 8: 47-54. Russian.
14. Akimovich VV, Shanina LN. Yersinia pestis strains that does not produce capsular antigen. Problems Microbiol Lab Diagn EDD Saratov 1965; 54-58. Russian.
15. Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994; 12: 727-730.
16. Ginsburg NN. Live vaccines. History, elements of the theory, and practice. Moscow: Medicina, 1969.
17. Keim P, Price LB, Klevytska AM et al. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J Bacteriol 2000; 182: 2928-2936.
18. Aleksandrov NI, Gefen NE, Gapochko KG et al. [Aerosol immunization with dried live vaccines and toxoids. VI. A study of postvaccination reactions and immunological efficacy of aerosol immunization with aerosol brucellosis, tularemia, anthrax and plague vaccines in man.] Zh Mikrobiol Epidemiol Immunobiol 1961; 32 : 1245-1252.
19. Sadovoi NV, Kravets ID, Selivanenko GM. [Vaccine anthrax combined.] Patent Russian Federation No. 2115433 (08.28.1992). Russian.
20. The All-Russian State Center for Quality and Standardization of Veterinary Drugs and Feed (VGNKI). Catalog cultures of the Russian State Collection of Microorganisms. Moscow: VGNKI, 2010. Available at http://www.vgnki.ru/structure/subdivisions/otdelenie-biologicheskih-lekarstvennyh-sredstv-i-biotehnologii/collection-of-microorganisms/katalog/shtammy-bakterij-1-chast/ (accessed 30 August 2010).
21. Ellis J, Oyston PC, GreenM et al. Tularemia. Clin Microbiol Rev 2002; 15: 631-646.
22. Elbert BJ, Gaiski NA. [On the mechanic of infection and immunity in experimental tularemia.] Zh Mikrobiol Epidemiol Immunobiol 1945; 7-8: 55-56. Russian.
23. Olsufiev NG, Rudnev GP. Tularemia. Moscow: Medgiz, 1960.
24. Sjostedt A, Tarnvik A, Sandstrom G. Francisella tularensis: host-parasite interaction. FEMS Immunol Med Microbiol 1996; 13: 181-184.
25. Eaves-Pyles T. The progress and promise of new tularemia vaccines. In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens. Kerala: Research Signpost, 2011: 235-258.
26. Firstova VV, Kravchenko TB, Zyrina EB et al. [Evaluation of T-cell and humoral postvaccinal specific immunity in humans who are regularly vaccinated against tularemia on prophylactic reason.] Life Without Danger 2012; 2: 96-102. Russian.
27. DzhaparidzeMN, Nikitina GP, Kulikova VL et al. [Choleragen-anatoxin chemical cholera vaccine enriched with Ogawa O-antigen]. Zh Mikrobiol Epidemiol Immunobiol 1984; 4: 70-74. Russian.
28. Sumarokov AA, Ivanov NR, Dzhaparidze MN et al. [The determination of the optimal inoculation dose of an oral cholera chemical bivalent vaccine in a controlled experiment.] Zh Mikrobiol Epidemiol Immunobiol 1990; 12: 55-62. Russian.
29. Sumarokov AA, Dzhaparidze MN, Eliseev IuIu et al. [The determination of the optimal inoculation dose of an oral cholera bivalent chemical vaccine in a controlled trial of the vaccination of children and adolescents.] Zh Mikrobiol Epidemiol Immunobiol 1993; 5: 55-60. Russian.
30. Sumarokov AA, Ivanov NR, Lelikov VL et al. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination.] Zh Mikrobiol Epidemiol Immunobiol 1978; 12: 87-92. Russian.
31. Dzhaparidze MN, Egorova VD, Karaeva LT et al. [A study of immunological efficacy of the oral chemical cholera vaccine on experimental animals.] Zh Mikrobiol Epidemiol Immunobiol 1976; 11: 115-119. Russian.
32. Kamzolkina NB, Karaeva LT, Dzhaparidze MN. [Serologic interrelations of choleragen and the neurotoxins of enterobacteria.] Zh Mikrobiol Epidemiol Immunobiol 1975; 12: 50-54. Russian.
33. Fedorova VA, Syrova NA, Gromova OV et al. [Synthesis of protective antigens during submerged cultivation of Vibrio cholerae.] Zh Mikrobiol Epidemiol Immunobiol 2000; 6: 72-74. Russian.
34. Fyodorova VA, Syrova NA, Gromova OV et al. [The use of dot immunoassay in the control of the synthesis of immunogens during the production of anti-cholerae chemical oral vaccine.] Biotechnology 2000; 4: 87-94. Russian.
35. Naumov AV, Popova AE, Anisimova TI et al. Method for protection of livestock from colibacteriosis and salmonellosis. Patent RF No. 2020958. Moscow: Ruspatent, 1994. Available at http://www.findpatent.ru/patent/202/2020958.html (accessed 10 February 2004).
36. Kovtun AL, Darmov IV, Bogatcheva NV et al. [Glanders vaccine: development, clinical trials, and recommendation for the use.] Epidemiol Vaccin Prev 2006; 4: 39-46. Russian.
37. Manzeniuk IN, Ganina EA, Dorokhin VV et al. [Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines.] Antibiot Khimioter 1999; 44: 21-26. Russian.
38. Khomiakov IuN, Manzeniuk IN, Naumov DV et al. [The principles of the therapy of glanders in monkeys.] Zh Mikrobiol Epidemiol Immunobiol 1998; 1: 70-74. Russian.
39. Vershilova PA, Golubeva AA, Kaitmazova EI et al. Brucellosis. Moscow: Medgiz, 1961. Russian.
40. Corbel MJ, Feodorova VA. Vaccines against human brucellosis. In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens. Kerala: Research Signpost, 2011: 59-92.
41. Sumarokov AA, Karinskaia GA, Dranovskaia EA et al. [Comparative study of the safety, reactogenicity and antigenic activity of chemical and live brucellosis vaccines in a controlled epidemiological trial.] Zh Mikrobiol Epidemiol Immunobiol 1984; 2: 58-63. Russian.
42. Vershilova PA, Dranovskaia EA, Karinskaia GA et al. [Determination of the optimal inoculation dose of Brucella chemical vaccine.] Zh Mikrobiol Epidemiol Immunobiol 1982; 10: 59-65. Russian.
43. Kulakov YK, Zheludkov MM, Sclyarov OD. Variable-number tandem repeat markers for identification of Brucella abortus 82 and 75/79-AV vaccine strains. Vaccine 2010; 28 Suppl 5: F41-F45.
44. Pashaeva SA. [Therapeutic brucellosis vaccine for an immunotherapy the patients with chronic brucellosis.] Proceeding of the 2nd Intern Conference dedicated to the 100th Anniversary of Perm Company "Biomed", 1-3 March, 1998; Perm, Russia. BioMed Press, Perm, Russia, 1998, pp57-58. Russian.
45. Shabalin BA, Okhapkina VYu, Gavrilova LB. [Combined brucellosis therapy with antibacterial preparations and therapeutic brucellosis vaccine.] Chem Biol Saf 2007; 2-3: 42-48. Russian.
46. Ostrovsky N. Brucellosis. In: Yushchuk ND, M. Vengerov YY, (eds.) Brucellosis - lectures on infectious diseases. Columbus, OH: JSC 'Publisher' Medicine, 2007: 413-427. Russian.
47. Konyushkova AN, Savchenko AY, Davydova KS, Ramenskaya GV, Kukes VG. [Overview of requirements for bioequivalence studies of generics. Requirements FDA.] Remedium 2011; 5: 54-56. Russian.
48. Saltykov RA, Motornaia VP, Sirotiuk LV. [Experience of a 25-year study of the stability of properties of tularemia vaccine strains.] Zh Mikrobiol Epidemiol Immunobiol 1972; 49: 64-70. Russian.
49. Onishchenko GG, Lazikova GF. [Legal basis of vaccine prophylaxis in Russia.] Zh Mikrobiol 1998; 6: 46-48. Russian.
50. Onishchenko GG. [Actual problems of infectious diseases prevention at present time.] Zh Mikrobiol Epidemiol Immunobiol 2010; 4: 13-22. Russian.
51. Feodorova VA, Corbel MJ. Prospects for new plague vaccines. Expert Rev Vaccines 2009; 8: 1721-1738.
52. Feodorova VA, Ulyanova OV. Development of diagnostic kits and vaccines for bacterial infections. In: Georgiev VS, Western KA, McGowan JJ (eds.) National Institute of Allergy and Infectious Diseases, NIH, Vol 1: Frontiers in Research. Totowa: Humana Press, 2008: 241-248.
53. Dentovskaia SV, Kopylov PKh, Ivanov SA et al. [A molecular basis of the plague vaccine development.] Mol Gen Mikrobiol Virusol 2013; 3: 3-12. Russian.
54. Dalvadyants SM. [Characteristics of somatic antigen isolated from avirulent, non-capsular and non-toxic strains of Y. pestis using the method of Boivin.] Problems Part Danger Dis (Saratov) 1968; 2: 134-138. Russian.
55. Dalvadyants SM, Dyatlov IA, Yeremin SA et al. [Plague immunization studies. Communication 4. An experience of volunteer revaccination with the 'chemical' and live plague vaccines.] Problems Part Danger Dis (Saratov) 2006; 1: 57-62. Russian.
56. Byvalov AA, Yevstigneev VI, Darmov IV et al. [Antigenic composition of plague chemical vaccine.] Patent Russian Federation No. 2190424 (07.18.2001). Russian.
57. Feodorova VA, Devdariani ZL. Immunogeneity and structural organisation of some pLCR-encoded proteins of Yersinia pestis. J Med Microbiol 2001; 50: 13-22.
58. Feodorova VA, Devdariani ZL. [Prospects for experimental anti-idiotype vaccine against plague.] Immunology 2006; 3: 144-148. Russian.
59. Feodorova VA, Devdariani ZL, Nazarova LS. Adjuvant effect of anti-idiotypic antibodies to Yersinia pestis lipopolysaccharide. J Med Microbiol 1999; 48: 751-756.
60. Kogotkova OI, Overchenko VV, Efremenko VI et al. [Increase in efficacy of antibiotic therapy of anthrax under experimental conditions.] Antibiot Khimioter 2002; 47: 27-30. Russian.
61. Taran TV. Development of conditions for drugs and immunogenic liposomal formulations that can be used for the treatment of experimental extremely dangerous infections as immunotherapeutic agents. DSc thesis, Stavropol API, Stavropol, Russia, 2004.
62. Smirnova NI, Krepostnova IM, Livanova LF. [An avirulent Vibrio cholerae strainproducer of the cholera toxin B subunit: obtaining and molecular genetic analysis.] Mol Gen Mikrobiol Virusol 2007; 4: 7-13. Russian.
63. Smirnova NI, Livanova LF, Chekhovskaia GV et al. [Strains of Vibrio cholerae serogroups O1 and O139 that produce the basic protective antigens.] Zh Mikrobiol Epidemiol Immunobiol 2000; 3: 47-51. Russian.
64. Toporkov AV, Zadnova SP, Smirnova NI. [Comparative analysis of the major protective antigens production in Vibrio cholerae recombinant and producer strains of the classical biovar.] Zh Mikrobiol Epidemiol Immunobiol 2005; 1: 53-57. Russian.
65. Zadnova SP, Toporkov AV, Smirnova NI. [Isolation and phenotyping of Vibrio cholerae strains with the enhanced production of main protective antigens.] Zh Mikrobiol Epidemiol Immunobiol 2001; 2: 3-6. Russian.
66. Dzhaparidze MN, Naumov AV, Gromova OV et al. [The use of a new strain of Vibrio cholerae O139 as a producer of an enteric chemical vaccine.] Zh Mikrobiol Epidemiol Immunobiol 1996; 2: 52-55. Russian.
67. Fedorova VA, Tereshkina NE, Gromova OV et al. [New methods for the control of the synthesis of immunogens during the production of the chemical vaccine against cholera caused by Vibrio cholerae O139.] Biotecnology 1999; 2: 82-88. Russian.
68. Fedorova VA, Devdariani ZL, Gromova OV et al. [Some immunochemical and immunobiological properties of Vibrio cholerae serovar 0139 capsule antigen.] Mol Gen Mikrobiol Virusol 1997; 3: 18-20. Russian.
69. Markov EIu, Urbanovich LIa, GolubinskiѤ EP et al. [The outer membranes of Vibrio cholerae as a potential component in a chemical vaccine.] Zh Mikrobiol Epidemiol Immunobiol 1995; Suppl 2: 86-89. Russian.
70. Eko FO, Schukovskaya T, Lotzmanova EY et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 2003; 21: 3663-3674.
71. Nisjegorodsev SA. The development of new technology of O-antigen for the production of cholera bivalent chemical tableted vaccine. PhD thesis, Saratov State Agrarian University, Saratov, Russia, 2003.
72. Ulianov AS. Improving the production of cholera bivalent chemical tableted vaccine. PhD thesis, Saratov State Agrarian University, Saratov, Russia, 2011.
73. Mott TM, Estes DM, Torres AG. Recent progress in the development of vaccines for glanders and melioidosis. In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens. Kerala: Research Signpost, 2011: 93-110.
74. Zhukov SI, Demyan OB, Avrorova IV et al. [Comparative effectiveness integrated liposomal antigenic drugs immunization experimental melioidosis.] Infect Immun 2012; 2: 102. Russian.
75. Kravchenko TB, Platonov ME, Vahrameeva GM et al. [Cloning and expression of protective antigens of Mycobacterium tuberculosis Ag85B and ESAT-6 in Francisella tularensis 15/10.] Biochemistry (Mosc) 2007; 72: 735-743. Russian.
76. Pavlov VM, Mokrievich AN, Noskov AN et al. [Tularemia vaccine strain is a potential vector.] Vestn Ross Akad Med Nauk 1997; 6: 30-32. Russian.
77. Pavlov VM. Methodology and results of molecular genetic study vaccine strain Francisella tularensis. DSc thesis, State Research Center for Applied Microbiology & Biotechnology, Obolensk, Russia, 2011.
78. Mikshis NI, Popova PIu, Kudriavtseva OM et al. [Immunogenicity of protective antigen extracted from asporogenic recombinant strain Bacillus anthracis.] Zh Mikrobiol Epidemiol Immunobiol 2011; 1: 44-48. Russian.
79. Mikshis NI, Kudriavtseva OM, Bolothikova MF et al. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis.] Mol Gen Mikrobiol Virusol 2007; 3: 15-21. Russian.